-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
VERU ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Veru Inc. Shareholders
VERU ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Veru Inc. Shareholders
NEW YORK, Jan. 17, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Veru Inc. (NASDAQ: VERU) alleging that the Company violated federal securities laws.
This lawsuit is on behalf of all investors who purchased or otherwise acquired Veru Inc. common stock between May 11, 2022 and November 9, 2022, inclusive.
Lead Plaintiff Deadline: February 6, 2023
No obligation or cost to you.
Learn more about your recoverable losses in VERU:
Veru Inc. NEWS - VERU NEWS
CLASS ACTION CASE DETAILS: The filed complaint alleges that Veru Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) the Company had withheld material adverse facts about the data from the sabizabulin Phase 3 trial and the Company's interactions with the United States Food and Drug Administration; 2) defendants misled Veru's shareholders to believe that the data from the sabizabulin Phase 3 trial was sufficient to support Emergency Use Authorization ("EUA") and even the submission of a New Drug Application without any further studies; and 3) the Company's filings concealed the true risks faced by Veru in gaining approval for its EUA request.
WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Veru you have until February 6, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you purchased Veru securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.
HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the VERU lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link:
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
535 Fifth Avenue
4th Floor
New York City, NY 10017
[email protected]
Telephone: (212) 616-4899
SOURCE The Klein Law Firm
NEW YORK, Jan. 17, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Veru Inc. (NASDAQ: VERU) alleging that the Company violated federal securities laws.
紐約, 2023 年一月十七日 /PRNewswire/-克萊因律師事務所宣布,已代表 Viru Inc.(納斯達克代碼:VERU)的股東提出集體訴訟投訴,指稱該公司違反了聯邦證券法。
This lawsuit is on behalf of all investors who purchased or otherwise acquired Veru Inc. common stock between May 11, 2022 and November 9, 2022, inclusive.
Lead Plaintiff Deadline: February 6, 2023
No obligation or cost to you.
此訴訟代表所有購買或以其他方式獲得 Vuru Inc. 普通股的投資者 2022年5月11日 和 2022年11月9日,包容性。
領導原告截止日期: 2023年2月6日
對您沒有任何義務或成本。
Learn more about your recoverable losses in VERU:
了解更多有關您在 VERU 中可恢復的損失的信息:
Veru Inc. NEWS - VERU NEWS
維魯公司新聞-最新消息
CLASS ACTION CASE DETAILS: The filed complaint alleges that Veru Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) the Company had withheld material adverse facts about the data from the sabizabulin Phase 3 trial and the Company's interactions with the United States Food and Drug Administration; 2) defendants misled Veru's shareholders to believe that the data from the sabizabulin Phase 3 trial was sufficient to support Emergency Use Authorization ("EUA") and even the submission of a New Drug Application without any further studies; and 3) the Company's filings concealed the true risks faced by Veru in gaining approval for its EUA request.
集體訴訟案件詳情: 提起的投訴指,Veru Inc. 作出重大虛假和/或誤導性陳述和/或未能披露:1)公司已經拒絕了來自 Sabizabulin 第三期試驗的數據以及公司與美國食品藥品管理局的互動的重大不良事實;2)被告誤導 Veru 的股東認為來自 Sabizabulin 第 3 期授權的數據足以支持緊急試驗(「緊急使用」)甚至在沒有任何進一步研究的情況下提交新藥申請; 和 3)公司的文件掩蓋了 Vuru 在獲得其 EUA 請求批准時所面臨的真實風險。
WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Veru you have until February 6, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
這對您作為股東意味著什麼: 如果您在 Veru 遭受了損失,那麼您必須直到 2023年2月6日 向法院呈請領導原告人的身份。您在任何恢復中分享的能力並不需要您擔任主要原告。
NO COST TO YOU: If you purchased Veru securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.
您無需支付任何費用:如果您在相關期間購買了 Vuru 證券,您可能有資格獲得賠償,而無需支付任何自付費用。
HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the VERU lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link:
如何保障您的財務利益: 如需有關 VERU 訴訟的其他資訊,請致電 212-616-4899 或按一下此連結聯絡:
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.
J· 克萊因(J.Klein)代表投資者並參與全國各地涉及金融欺詐的證券訴訟。Klein 律師事務所是一家精品訴訟事務所,在證券法、企業融資和商業訴訟等廣泛領域擁有豐富經驗。自 2011 年以來,我們經驗豐富的律師以個性化的重點為我們的客戶取得了卓越的成績。律師廣告。先前的結果不能保證類似的結果。
CONTACT:
J. Klein, Esq.
535 Fifth Avenue
4th Floor
New York City, NY 10017
[email protected]
Telephone: (212) 616-4899
聯絡人:
J. 克萊因,埃斯基。
第五大道 535 號
四樓
紐約市, 紐約
[電子郵件保護]
電話:
SOURCE The Klein Law Firm
來源克萊因律師事務所
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧